Silas Inman

Silas is the senior vice president, content, at MJH Life Sciences. He began his career at MJH in 2011 as a Web Editor on OncLive. From this role, he moved into managing the social media across the organization and then into broader roles across the content department, first taking on management of HCPLive.

Throughout his tenure at MJH, Silas has been accountable for several organic launches of highly successful brands, including Targeted Oncology and NeurologyLive, and for quickly transforming acquisitions into high-functioning business units. Follow him on X @SilasInman, LinkedIn, sinman@mjhlifesciences.com.

Articles

FDA Approves Earlier Use of Abiraterone Acetate

December 10th 2012

The FDA has approved abiraterone acetate in combination with prednisone prior to chemotherapy for the treatment of men with metastatic castration-resistant prostate cancer.

FDA Approves Synribo for CML

October 26th 2012

The FDA has approved omacetaxine mepesuccinate for the treatment of adult patients with Philadelphia chromosome-positive CML who have progressed after treatment with at least two prior TKIs.

FDA Approves Nab-Paclitaxel for Advanced Lung Cancer

October 12th 2012

The FDA has approved nab-paclitaxel plus carboplatin for patients with untreated locally advanced or metastatic NSCLC who are not candidates for surgery or radiation.

Crizotinib Active in ALK-Positive Pediatric Cancers

May 16th 2012

Targeting the ALK gene with the oral agent crizotinib slowed or eliminated signs of tumor growth in pediatric patients with aggressive forms of neuroblastoma, ALCL, and IMTs.

Zytiga Study Unblinded Following Positive Interim Analysis

March 9th 2012

A phase III study of abiraterone acetate in chemotherapy-naive patients with mCRPC has been unblinded following a positive interim analysis.

FDA Takes Aggressive Steps to Reduce Drug Shortages

February 21st 2012

The FDA announced plans to strengthen the supply of 2 scarce cancer drugs: methotrexate and Doxil.

ODAC Unanimously Supports Axitinib for Renal Cell Carcinoma

December 8th 2011

ODAC unanimously voted to recommend the approval of axitinib for the second-line treatment of patients with advanced renal cell carcinoma.

FDA Grants Orphan Drug Status to Erwinaze for Treatment of Acute Lymphoblastic Leukemia

November 18th 2011

The FDA granted orphan drug approval to Erwinaze (asparaginase Erwinia chrysanthemi) to treat acute lymphoblastic leukemia (ALL).

Vemurafenib Receives Approval for Metastatic Melanoma

August 17th 2011

The FDA approved vemurafenib and a companion diagnostic test in a move that was hailed as an advance for both patients and personalized medicine.

Erlotinib Extends PFS in EGFR-Positive Lung Cancer

July 25th 2011

Findings from a randomized phase III trial in China suggest erlotinib is suitable for first-line treatment in patients with EGFR mutation-positive NSCLC.

FDA Panel Unanimously Supports New Lymphoma Treatment

July 15th 2011

ODAC unanimously recommended accelerated approval for brentuximab vedotin (Adcetris) in 2 types of lymphoma.

Amgen Seeks to Expand Xgeva's FDA Approval

July 11th 2011

A pivotal phase III study found that men with CRPC experienced prolonged bone metastasisâ€“free survival with Xgeva versus placebo.

NCI Examines Cediranib to Fight Metastatic Prostate Cancer

July 7th 2011

Prostate cancer metastases, or cancer growing outside the prostate glands, can occur in any organ but is seen most frequently in the bone.

Celecoxib: Effective in Former Smokers as Lung Cancer Chemoprevention

July 6th 2011

A recent study revealed that celecoxib (Celebrex), a COX-2 inhibitor, might be a successful lung cancer chemoprevention in former smokers.

New Genetic Test Aids Detection of HER2+ Breast Cancer

June 15th 2011

On Tuesday the FDA approved a genetic test known as Inform Dual ISH that detects HER2+ breast cancer